Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (51-60 of 220) with videos related to

Pageof 22
Sort By:
Cancer|September 1, 2005
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trialJohn D Hainsworth, David R Spigel, Eric L Raefsky, et al.
Cancer Investigation|August 2, 2017
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)David R Spigel, Tarek M Mekhail, David Waterhouse, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancerRavi Salgia, John R Stille, R Waide Weaver, et al.
Targeted Oncology|November 10, 2025
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung CancerMelissa L Johnson, Shaker R Dakhil, J Thaddeus Beck, et al.
Clinical Lung Cancer|June 7, 2016
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung CancerDavid E Gerber, David R Spigel, David Giorgadze, et al.
Cancer|September 8, 2007
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, Cindy Farley, et al.
Cancer|March 9, 2010
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
The Oncologist|December 8, 2009
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary siteJohn D Hainsworth, David R Spigel, Dana S Thompson, et al.
Clinical Breast Cancer|March 21, 2009
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancerJeffrey R Infante, Denise A Yardley, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumabDavid R Spigel, John D Hainsworth, Denise A Yardley, et al.
Pageof 22

Showing results (51-60 of 220) with videos related to

Sort By:
Pageof 22
Cancer|September 1, 2005
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trialJohn D Hainsworth, David R Spigel, Eric L Raefsky, et al.
Cancer Investigation|August 2, 2017
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)David R Spigel, Tarek M Mekhail, David Waterhouse, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancerRavi Salgia, John R Stille, R Waide Weaver, et al.
Targeted Oncology|November 10, 2025
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung CancerMelissa L Johnson, Shaker R Dakhil, J Thaddeus Beck, et al.
Clinical Lung Cancer|June 7, 2016
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung CancerDavid E Gerber, David R Spigel, David Giorgadze, et al.
Cancer|September 8, 2007
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, Cindy Farley, et al.
Cancer|March 9, 2010
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
The Oncologist|December 8, 2009
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary siteJohn D Hainsworth, David R Spigel, Dana S Thompson, et al.
Clinical Breast Cancer|March 21, 2009
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancerJeffrey R Infante, Denise A Yardley, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumabDavid R Spigel, John D Hainsworth, Denise A Yardley, et al.
Pageof 22